By: Sruthy Iype  Sep. 07, 2020

Dexur’s analysis of Medicare claims data showed that more than 50 percent of Tecentirq’s use is associated with the treatment of lung cancer patients, followed by patients of bladder cancer and breast cancer. The analysis looked at the J code (J9022) usage of the drug among Medicare patients who received outpatient care between Jan 2018 and Dec 2019. The analysis also looks at the average claims per patient data, which is a proxy for the number of injections / IV infusions / doses administered to a patient.

By: Sruthy Iype  Sep. 04, 2020

Dexur’s analysis of Medicare claims data showed that head and neck cancer accounts for nearly 50 percent of the total patients who were administered Erbitux, followed by colorectal cancer and squamous cell carcinoma of the skin. The analysis was based on the J code (J9055) usage of the drug among Medicare patients who received outpatient care between Jan 2017 and Dec 2019.

Erbitux (cetuximab) is a monoclonal antibody that belongs to the drug class called epidermal growth factor receptor (EGFR) inhibitors. The binding of epidermal growth factor to EGFR, a transmembrane protein found on the surface of cells, sets off a series of events that result in cell growth and differentiation. In certain types of cancer, the overexpression of EGFR was found to be responsible for unregulated cell proliferation and tumor growth. By targeting the receptor and blocking the events mediated by it, Erbitux helps in slowing down the progression and spread of the disease. It is approved as a targeted therapy, monotherapy or in combination with other drugs, in the treatment of certain types of colorectal, and head and neck cancer.

By: Parvathy Rajagopal  Sep. 04, 2020

Dexur’s analysis of Medicare claims of hospitals within a 10-mile radius of Colorado Springs, CO, showed that UCHealth Memorial Hospital Central and Penrose - St. Francis Health Services had the best value outcomes over a 90-day episode for Sepsis. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days, including the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. The total cost of care data helps patients make appropriate choices and helps local ACOs make appropriate referrals choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 871: Septicemia or Severe Sepsis without MV >96 Hours with Major Complication or Comorbidity, to adjust for complications and comorbidities.

By: Sruthy Iype  Sep. 03, 2020

Dexur’s analysis of Medicare claims data showed that Simponi Aria was used more in the treatment of rheumatoid arthritis as compared to psoriatic arthritis and ankylosing spondylitis. The analysis was based on the J code (J1602) usage of the drug among Medicare patients who received outpatient care between Jan and Dec 2019. The analysis also looks at the average claims per patient data, which is a proxy for the number of injections / IV infusions / doses administered to a patient.

By: Parvathy Rajagopal  Sep. 03, 2020

Dexur’s analysis of medicare claims of hospitals within a 10-mile radius of Medford, Oregon, showed that Providence Medford Medical Center and Asante Rogue Regional Medical Center had the best value outcomes over a 90 day episode for Hip & Knee replacement. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. Total cost of care data helps patients make appropriate choices and helps local ACOs make appropriate referral choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 470: Major Joint Replacement or Reattachment of Lower Extremity without Major Complication or Comorbidity (MCC), to adjust for complications and comorbidities.

By: Sruthy Iype  Sep. 02, 2020

Dexur’s analysis of Medicare claims data showed that Cimzia was used more in the treatment of rheumatoid arthritis, as compared to psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease. The analysis was based on the J code (J0717) usage of the drug among Medicare patients who received outpatient care between Jan and Dec 2019. The analysis also looks at the average claims per patient data, which is a proxy for the number of injections / IV infusions / doses administered to a patient.

By: Neha Thomas  Sep. 02, 2020

Dexur’s analysis of medicare claims of hospitals within a 10-mile radius of Port Huron, Michigan, showed that Lake Huron Medical Center and McLaren Port Huron had the best value outcomes over a 90 day episode for Sepsis. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. Total cost of care data helps patients make appropriate choices and helps local ACOs make appropriate referral choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 871: Septicemia or Severe Sepsis without MV >96 Hours with Major Complication or Comorbidity, to adjust for complications and comorbidities.

By: Parvathy Rajagopal  Sep. 01, 2020

Dexur’s analysis of medicare claims of hospitals within a 10-mile radius of Lafayette, Louisiana, showed that Our Lady of Lourdes Regional Medical Center and Lafayette General Medical Center had the best value outcomes over a 90 day episode for Heart Failure. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. Total cost of care data helps patients make appropriate choices and helps local ACOs like Lafayette General Health ACO, LLC, make appropriate referral choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 291: Heart Failure and Shock with Major Complication or Comorbidity (MCC), to adjust for complications and comorbidities.

By: Parvathy Rajagopal  Aug. 31, 2020

Dexur’s analysis of Medicare claims of hospitals within a 10-mile radius of Springfield, Oregon showed that McKenzie-Willamette Medical Center and Sacred Heart Medical Center at Riverbend had the best value outcomes over a 90-day episode for Sepsis. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days, including the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. The total cost of care data helps patients make appropriate choices and helps local ACOs make appropriate referrals choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 871: Septicemia or Severe Sepsis without MV >96 Hours with Major Complication or Comorbidity, to adjust for complications and comorbidities.

By: Parvathy Rajagopal  Aug. 31, 2020

Dexur’s analysis of Medicare claims of hospitals within a 10-mile radius of Olympia, Washington showed that Capital Medical Center and Providence St. Peter Hospital had the best value outcomes over a 90-day episode for Sepsis. Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days, including the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. The total cost of care data helps patients make appropriate choices and helps local ACOs make appropriate referrals choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 871: Septicemia or Severe Sepsis without MV >96 Hours with Major Complication or Comorbidity, to adjust for complications and comorbidities.